Advanced Biomed Inc. Announces Pricing of Initial Public Offering
Rhea-AI Summary
Advanced Biomed has announced the pricing of its Initial Public Offering (IPO) of 1,640,000 common stock shares at $4.00 per share, expecting to raise gross proceeds of $6.56 million. The shares will trade on the Nasdaq Capital Market under ticker symbol ADVB starting March 6, 2025.
The biotechnology company, focused on cancer screening, detection, diagnosis, and treatment, has granted underwriters a 45-day option to purchase up to additional 246,000 shares. The offering is expected to close around March 7, 2025.
Proceeds will fund:
- IVD clinical research, chip design and development
- Facility upgrades and market expansion
- Marketing and sales initiatives
- General working capital
Positive
- Successfully secured Nasdaq Capital Market listing
- Raised $6.56M in gross proceeds
- Clear allocation of funds for product development and expansion
- Firm commitment offering structure
Negative
- Relatively small IPO size of $6.56M
- Potential dilution from additional 246,000 shares option
- Early-stage company requiring significant capital deployment
Insights
Advanced Biomed's IPO represents a modest capital raise in the biotechnology sector with $6.56 million in gross proceeds from 1,640,000 shares at $4.00 each. This positions the offering at the smaller end of the biotech IPO spectrum, where companies typically raise $50-100+ million to fund comprehensive R&D programs.
The Nasdaq Capital Market listing under ticker "ADVB" provides the Taiwan-based cancer-focused company with public market access and potential future funding opportunities. However, the underwriter structure merits attention - while Craft Capital Management's firm commitment basis ensures funding certainty, the absence of larger, specialized biotech investment banks in the syndicate might suggest institutional appetite.
The allocation of proceeds across multiple initiatives (IVD clinical research, chip design, facility upgrades, marketing, and working capital) indicates a broad dispersal of capital rather than concentration on advancing a single program. This diversified approach could present execution challenges given the relatively small raise. The additional 45-day option for underwriters to purchase 246,000 more shares could potentially increase proceeds by approximately $984,000 if fully exercised.
Advanced Biomed's integrated approach spanning cancer screening, diagnosis, and treatment represents an ambitious strategy in oncology. The emphasis on in-vitro diagnostics (IVD) clinical research and chip design suggests a technology platform potentially focused on biomarker detection or liquid biopsy approaches, which have become increasingly important in precision oncology.
The funding allocation priorities reveal an early-stage company still in development rather than commercialization phase. Clinical research funding as a primary use indicates ongoing validation efforts rather than market-ready products. The chip development focus suggests a proprietary diagnostic technology that could differentiate them in the competitive cancer detection market.
For a company addressing multiple aspects of the cancer care continuum, the $6.56 million raise represents modest capitalization that will likely require supplemental funding rounds as programs advance. Without specific details on their technology platform's current validation status or regulatory pathway progress, investors will need to closely monitor milestone achievements to gauge capital efficiency. The Taiwan base of operations may offer manufacturing advantages but could also present unique considerations for global regulatory approval pathways.
Tainan, Taiwan, March 06, 2025 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (the “Company” or “Advanced Biomed”), a biotechnology company focused on early screening and detection, diagnosis and staging, and treatment of cancer, today announced the pricing of its initial public offering (the “Offering”) of 1,640,000 shares of common stock (“Common Stock”) at a public offering price of
The Company expects to receive aggregate gross proceeds of US
Proceeds from the Offering will be used for: (i) invitro diagnostics (IVD) clinical research, chip design and development, upgrade facilitates, and expansion to other markets; (ii) marketing and sales, and (iii) general working capital.
The Offering is being conducted on a firm commitment basis. Craft Capital Management LLC is acting as the underwriter for the Offering (the “Underwriter”). VCL Law LLP is acting as U.S. counsel to the Company, and Ortoli Rosenstadt LLP is acting as U.S. counsel to the Underwriter in connection with the Offering.
A registration statement on Form S-1 relating to the Offering was filed with the U.S. Securities and Exchange Commission (the “SEC”) (File Number: 333-272110), as amended, and was declared effective by the SEC on February 11, 2025. The Offering is being made only by means of a prospectus, forming a part of the registration statement. Copies of the final prospectus relating to the Offering, when available, may be obtained from Craft Capital Management LLC by email at info@craftcm.com, by standard mail to 377 Oak St, Lower Concourse, Garden City, NY 11530, or by telephone at +1 (800) 550-8411. In addition, copies of the final prospectus relating to the Offering, when available, may be obtained via the SEC's website at www.sec.gov.
Before you invest, you should read the prospectus and other documents the Company has filed or will file with the SEC for more information about the Company and the Offering. This press release does not constitute an offer to sell, or the solicitation of an offer to buy any of the Company’s securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of any of the Company’s securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.
About Advanced Biomed Inc.
Since 2014, Advanced Biomed Inc. has been focusing on the integration of multiple interdisciplinary technologies and established its own microfluidic technology platform. The Company aims to provide rapid and affordable assay products and services to cancer patients. The Company has a range of innovative devices, including A+Pre, AC-1000, A+CellScan, and A+SCDrop, along with three corresponding biochips: A+Pre Chip, AC-1000 CTC Enrichment Chip, and A+CellScan Chip. The Company’s technologies and products can be used for early screening and detection, diagnosis and staging, and treatment of cancer through the detection of circulating tumor cells and related tumor markers in blood samples, capture of single circulating tumor cells, and single-cell sorting and determination. Additionally, the Company has completed the research and development stage for four matching immunostaining kits, A+CTCE, A+CTCM, A+EMT, and A+CM, utilizing multiplexed staining with fluorescent-labeled antibodies to identify tumor cell types. The Company has also introduced A+LCGuard, a product designed for early screening of lung cancer to assist in the determination of benign and malignant pulmonary nodules. With the Company's primary operations, design, and development based in Taiwan, Advanced Biomed is expanding in China while preparing for the establishment of operation centers in North America and Europe. For more information, please visit the Company’s website: http://ir.advanbiomed.com/.
Forward-Looking Statements
Certain statements in this announcement are forward-looking statements, including, but not limited to, the Company's proposed Offering. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs, including the expectation that the Offering will be successfully completed. Investors can find many (but not all) of these statements by the use of words such as “could,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “project” or other similar expressions in this prospectus. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the SEC.
For more information, please contact:
Advanced Biomed Inc.
Investor Relations Department
Email: ir@advanbiomed.com
Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com
FAQ
What is the IPO price and size for Advanced Biomed (ADVB) stock?
When will ADVB stock begin trading on Nasdaq?
How will Advanced Biomed use the IPO proceeds?
What is the additional share option granted to ADVB underwriters?
What is Advanced Biomed's main business focus?
